- Home
- NCPL vs CANF Comparison
NCPL vs CANF Comparison
Compare NCPL & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCPL | CANF |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | Israel |
| Employees | 20 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.0M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | NCPL | CANF |
|---|---|---|
| Price | $0.47 | $3.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 127.2K | ★ 1.8M |
| Earning Date | 03-19-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $739.37 | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.17 |
| 52 Week High | $7.05 | $10.40 |
Technical Indicators
Market Signals| Indicator | NCPL | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 51.18 |
| Support Level | $0.35 | $2.88 |
| Resistance Level | $0.58 | $3.42 |
| Average True Range (ATR) | 0.06 | 0.51 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 5.67 | 22.81 |
Price Performance
Historical ComparisonAbout NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.